Results of cross-reactivity by ATI levels for seven anti-adalimumab positive sera of patients with IBD unexposed to Remicade as measured towards two batches each of Remsima and Remicade
| Serum number | Anti-Remicade batch DGM54013 ATI (μg/mL) | Anti-Remicade batch 2RMKA83001ATI (μg/mL) | Anti-Remsima batch 12B1C017 ATI (μg/mL) | Anti-Remsima batch 12B1C019 ATI (μg/mL) |
|---|---|---|---|---|
| 3931 | 1 | 1 | 1.2 | 1.2 |
| 3863 | 1 | 0.9 | 1.3 | 1.2 |
| 3854 | 1.1 | 1 | 1 | 1.1 |
| 3835 | 1 | 1 | 1.2 | 1.2 |
| 3834 | 0.8 | 0.8 | 0.9 | 0.9 |
| 3811 | 1.6 | 1.7 | 2.3 | 2.3 |
| 3614 | 0.9 | 0.9 | 1 | 0.9 |
| 3754 | 15 | 14.7 | 17.8 | 16.3 |
A positive control (serum 3754) is a patient previously exposed to Remicade before adalimumab, who became sensitised to Remicade and adalimumab.
ATI, antibodies to infliximab.